Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma

NCT03063450 is registered in ClinicalTrials.gov with University of Southampton as lead sponsor.

NCT NCT03063450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03063450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma
Lead sponsor
University of Southampton
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2017
Completion date
February 7, 2023
Enrollment
332 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma